KR20190134809A - 베타 세크레타제 억제를 위한 조성물 및 방법 - Google Patents

베타 세크레타제 억제를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20190134809A
KR20190134809A KR1020197034396A KR20197034396A KR20190134809A KR 20190134809 A KR20190134809 A KR 20190134809A KR 1020197034396 A KR1020197034396 A KR 1020197034396A KR 20197034396 A KR20197034396 A KR 20197034396A KR 20190134809 A KR20190134809 A KR 20190134809A
Authority
KR
South Korea
Prior art keywords
secretase
oroxylin
chrysine
disease
bicalane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197034396A
Other languages
English (en)
Korean (ko)
Inventor
칼야남 나가브후스하남
무하메드 마지드
Original Assignee
새미 랩스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 새미 랩스 리미티드 filed Critical 새미 랩스 리미티드
Publication of KR20190134809A publication Critical patent/KR20190134809A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Confectionery (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197034396A 2017-06-15 2018-06-14 베타 세크레타제 억제를 위한 조성물 및 방법 Ceased KR20190134809A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520141P 2017-06-15 2017-06-15
US62/520,141 2017-06-15
PCT/US2018/037454 WO2018232063A1 (en) 2017-06-15 2018-06-14 Compositions and methods for beta secretase inhibition

Publications (1)

Publication Number Publication Date
KR20190134809A true KR20190134809A (ko) 2019-12-04

Family

ID=64655980

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020197034396A Ceased KR20190134809A (ko) 2017-06-15 2018-06-14 베타 세크레타제 억제를 위한 조성물 및 방법
KR1020197033007A Ceased KR20190131589A (ko) 2017-06-15 2018-06-15 신경보호 조성물 및 이의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197033007A Ceased KR20190131589A (ko) 2017-06-15 2018-06-15 신경보호 조성물 및 이의 용도

Country Status (9)

Country Link
US (2) US11458117B2 (enExample)
EP (2) EP3638277B1 (enExample)
JP (2) JP7209645B2 (enExample)
KR (2) KR20190134809A (enExample)
CA (2) CA3063751C (enExample)
ES (1) ES3005508T3 (enExample)
FI (1) FI3638277T3 (enExample)
PL (2) PL3638277T3 (enExample)
WO (2) WO2018232063A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018232063A1 (en) * 2017-06-15 2018-12-20 Muhammed Majeed Compositions and methods for beta secretase inhibition
US12465585B2 (en) * 2018-06-15 2025-11-11 Sami-Sabinsa Group Limited Compositions for the management of seizure induced neurotoxicity
CN110115712A (zh) * 2019-07-04 2019-08-13 兰州大学 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用
KR20220049575A (ko) * 2019-08-26 2022-04-21 새미-사빈사 그룹 리미티드 식물 활성물질 및 이의 오염 방지 효과
CN114246879B (zh) * 2021-12-30 2023-10-27 沈阳兴齐眼药股份有限公司 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
WO2003092599A2 (en) * 2002-04-30 2003-11-13 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
WO2005020932A2 (en) * 2003-09-02 2005-03-10 Unigen Pharmaceuticals, Inc. Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
JP2009527461A (ja) * 2006-01-09 2009-07-30 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 胃腸毒性、関連する症状及び潰瘍の処置のための天然作用物質
WO2007096739A2 (en) * 2006-02-21 2007-08-30 Council Of Scientific And Industrial Research Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof
EP2007385A4 (en) 2006-03-23 2010-08-18 Sinai School Medicine CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER
KR20080008929A (ko) * 2006-11-20 2008-01-24 대한민국(관리부서 식품의약품 안전청장) 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품
BR112015004418A2 (pt) * 2012-08-29 2017-07-04 Mannkind Corp composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit.
WO2018089325A1 (en) * 2016-11-11 2018-05-17 Muhammed Majeed Composition containing oroxylin a and method of extraction thereof
WO2018232063A1 (en) 2017-06-15 2018-12-20 Muhammed Majeed Compositions and methods for beta secretase inhibition

Also Published As

Publication number Publication date
PL3638278T3 (pl) 2022-10-03
JP7209645B2 (ja) 2023-01-20
US20180360800A1 (en) 2018-12-20
CA3063757A1 (en) 2018-12-20
CA3063751C (en) 2023-01-03
US20180360801A1 (en) 2018-12-20
US11458117B2 (en) 2022-10-04
PL3638277T3 (pl) 2025-03-10
JP2020523372A (ja) 2020-08-06
EP3638277A4 (en) 2021-03-17
EP3638277B1 (en) 2024-10-09
CA3063751A1 (en) 2018-12-20
ES3005508T3 (en) 2025-03-14
EP3638278A4 (en) 2021-03-17
EP3638277A1 (en) 2020-04-22
EP3638278A1 (en) 2020-04-22
JP6796217B2 (ja) 2020-12-02
WO2018232224A1 (en) 2018-12-20
KR20190131589A (ko) 2019-11-26
CA3063757C (en) 2023-08-01
WO2018232063A1 (en) 2018-12-20
JP2020523342A (ja) 2020-08-06
EP3638278B1 (en) 2022-05-11
US10894029B2 (en) 2021-01-19
FI3638277T3 (fi) 2025-01-10

Similar Documents

Publication Publication Date Title
Niranjan Molecular basis of etiological implications in Alzheimer’s disease: focus on neuroinflammation
Martín-Maestro et al. Slower dynamics and aged mitochondria in sporadic Alzheimer’s disease
KR20190134809A (ko) 베타 세크레타제 억제를 위한 조성물 및 방법
Dong et al. Advances in the pathogenesis of Alzheimer’s disease: a re-evaluation of amyloid cascade hypothesis
Porquet et al. Neuroprotective role of trans-resveratrol in a murine model of familial Alzheimer's disease
MacLeod et al. The role and therapeutic targeting of α-, β-and γ-secretase in Alzheimer's disease
Lahiri et al. Current drug targets for Alzheimer's disease treatment
Sivak The aging eye: common degenerative mechanisms between the Alzheimer's brain and retinal disease
Galimberti et al. Disease-modifying treatments for Alzheimer’s disease
Mori et al. Ferulic acid is a nutraceutical β-secretase modulator that improves behavioral impairment and alzheimer-like pathology in transgenic mice
Xu et al. Amyloid-β peptides are cytotoxic to oligodendrocytes
Grimm et al. The impact of cholesterol, DHA, and sphingolipids on Alzheimer’s disease
Prasad et al. Prostaglandins as putative neurotoxins in Alzheimer's disease
Yang et al. Complicated role of post-translational modification and protease-cleaved fragments of tau in Alzheimer’s Disease and other tauopathies
Perone et al. Mitochondrial SIRT3 deficiency results in neuronal network hyperexcitability, accelerates age-related Aβ pathology, and renders neurons vulnerable to Aβ toxicity
Jacobsen Alzheimer's disease: an overview of current and emerging therapeutic strategies
Bauer et al. γ-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by imatinib
Acewicz et al. Incidence and morphology of secondary TDP-43 proteinopathies: Part 1
Chiu et al. Progressive Neurodegeneration of Retina in Alzheimer’s Disease—Are β-Amyloid Peptide and Tau New Pathological Factors in Glaucoma?
US20250339422A1 (en) Methods for enhancing cellular clearance of pathological molecules via activation of the cellular protein ykt6
Ohm et al. Cholesterol, statins and tau
WO2008036733A2 (en) Methods for treatment of vesicle transport disorders
CN117202911A (zh) 包含作为活性成分的刺五加苷b的用于治疗神经炎症的药物组合物
Creed et al. Amyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications
Erdemci et al. Etiology and histopathology of Alzheimer’s disease and current approaches

Legal Events

Date Code Title Description
A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000